GenesisCare and PreMIT Collaborate to Identify and Pursue Clinical Research Opportunities in Theranostics and Molecular Imaging
In the lead up to World Theranostics Day this Friday, 31st March, GenesisCare, a leading global provider of integrated cancer care and research, and PreMIT, a Melbourne-based molecular imaging and theranostics research provider, are announcing a new strategic agreement to work together to identify and proactively pursue clinical research opportunities in the fields of molecular imaging and theranostics.
Theranostics is a personalised cancer treatment that combines diagnostics and therapies to detect and treat a wide range of cancers. World Theranostics Day celebrates ongoing innovation and advancement in the field of theranostics and is held every year on the 31st March, in recognition of the day the first radioiodine treatment was administered at Massachusetts General Hospital in 1941.
GenesisCare’s Chief Scientific Officer, Theranostics, Research & Insights, Dr Danielle Meyrick, said “over the last decade we have made significant progress in the advancement of theranostics in Australia, both in terms of the development of new therapies and advanced imaging technologies, as well as the emergence of a network of nuclear medicine physicians and physicists with the expertise and deep knowledge base to deliver the best possible care for patients.”
“GenesisCare hopes to unlock the full potential of theranostics both here in Australia and abroad, to ensure the patient benefits of these recent therapeutic and technological advancements are fully realised,” Dr Meyrick.
Professor Rodney Hicks, PreMIT Founder, Chairman, and Chief Medical Officer, said: “PreMIT is delighted to be partnering with GenesisCare, who share our vision of democratising and scaling patient access to theranostics and precision medicine worldwide.”
“Together, PreMIT and GenesisCare are seeking to develop a differentiated clinical trial capability to increase patient access to novel therapies, drive greater collaboration within the academic and biotechnology ecosystem, and facilitate efficient and integrated research data exchange.”
“We see a future where theranostics will become a key pillar of modern cancer medicine, however a concerted effort is required globally by medical experts, industry, academia and governments. Collectively, we need to build on the great progress we have already made, to collaborate, knowledge-share, and increase patient access to new therapies in a faster and more affordable way,” said Professor Hicks.